Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IHE
IHE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IHE News
Health Care ETFs Remain Unfazed by Price Reductions from Major Pharmaceutical Companies
Dec 19 2025
Benzinga
ETFs on the Move This Monday: IHE, BLOK
Dec 15 2025
NASDAQ.COM
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Dec 11 2025
MarketWatch
ETF Movers for Friday: SILJ, IHE
Nov 28 2025
NASDAQ.COM
Novo Nordisk's Stock Decline Highlights the Side Effect of GLP-1 Investments: ETF Concentration Risk
Nov 24 2025
Benzinga
Unusual Volume Noted in Monday's ETF: IHE
Nov 24 2025
NASDAQ.COM
Eli Lilly Dominance: The Impact of a Single Stock on Pharma ETF Performance
Nov 15 2025
Benzinga
Pharma ETFs Gain Attention After Strong Q3 Earnings Reports
Nov 14 2025
NASDAQ.COM
Eli Lilly CEO Criticizes PBM 'Rent-Seeking', Claims They Increased Insulin List Prices to $275: 'We Can Easily Bypass Them'
Nov 12 2025
Benzinga
Is Trump's MFN Policy Targeting Pharma ETFs?
Nov 10 2025
NASDAQ.COM
Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Oct 30 2025
Benzinga
Economist Warns Trump's Full Drug Tariff Will Burden Americans, Not Foreign Companies
Sep 29 2025
Benzinga
Mark Cuban Reveals How Wholesalers Coerce Pharmacies into Nearly Exclusive Agreements, Highlighting PBMs' 'Stranglehold' on Medication Costs
Sep 08 2025
Benzinga
Lilly's Obesity Pill Trial Results Receive Positive Response from Wall Street This Time
Aug 26 2025
MarketWatch
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Aug 08 2025
NASDAQ.COM
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Aug 01 2025
Benzinga
Show More News
